1.03
+0.03(+3.00%)
Currency In USD
| Previous Close | 1 |
| Open | 1.01 |
| Day High | 1.03 |
| Day Low | 1.01 |
| 52-Week High | 2.31 |
| 52-Week Low | 0.77 |
| Volume | 404,965 |
| Average Volume | 713,984 |
| Market Cap | 129.58M |
| PE | -4.9 |
| EPS | -0.21 |
| Moving Average 50 Days | 1.31 |
| Moving Average 200 Days | 1.39 |
| Change | 0.03 |
If you invested $1000 in Atossa Therapeutics, Inc. (ATOS) 10 years ago, it would be worth $3.04 as of December 26, 2024 at a share price of $1.03. Whereas If you bought $1000 worth of Atossa Therapeutics, Inc. (ATOS) shares 5 years ago, it would be worth $620.48 as of December 26, 2024 at a share price of $1.03.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Atossa Therapeutics to Present Poster Describing the Discovery of Molecules Synergistic with (Z)-endoxifen for the Treatment of Breast Cancer at the 2024 San Antonio Breast Cancer Symposium
GlobeNewswire Inc.
Dec 12, 2024 1:15 PM GMT
Insilico and Chemical Screening Identified Compounds that Synergize with (Z)-endoxifen to Induce Cell Death in MCF-7 Cells, Suggesting Potential Combination Therapies as Breast Cancer TreatmentsSEATTLE, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Atossa Ther
Atossa Therapeutics Announces Full Results from Phase 2 KARISMA-Endoxifen Study Demonstrating Statistically Significant Reductions in Mammographic Breast Density
GlobeNewswire Inc.
Dec 11, 2024 1:15 PM GMT
1 MG Dose (Z)-Endoxifen Shows Potential as a Well-Tolerated, Preventative Therapy for Premenopausal Women at Risk of Developing Breast Cancer Data to be Presented in a Poster Spotlight Session During the 2024 San Antonio Breast Cancer Symposium SEAT
Atossa Therapeutics to Present Pharmacokinetic and Tolerability Data from Phase 2 EVANGELINE Trial at the 2024 San Antonio Breast Cancer Symposium
GlobeNewswire Inc.
Dec 10, 2024 2:05 PM GMT
SEATTLE, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with